10.
The information shall at least include: a valid EU trial number; a sponsor study number; an identifiable coded subject; an identifiable reporter; a SUSAR; a suspect investigational medicinal product (including active substance name-code); a causality assessment.
← 2.3. Information for the reporting of SUSARs · All articles · anx_III__cpt_2__cpt_3__point_10__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.